1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Early VC Forecast Predicts Reduced Investment In 2023

Last Biopharma Mega-Round Was Early December

 
• By Mandy Jackson

Private Company Edition: Pitchbook is out with an early look at its venture capital expectations for next year, showing continued interest in seed financings and fewer $100m-plus mega-rounds. Recent VC deals include a $75m series B financing for Alpha-9 Theranostics and $71.6m for A2 Biotherapeutics. 

Finance Watch Private Company
• Source: Shutterstock

It is too soon for the Pitchbook and National Venture Capital Association (NVCA) Venture Monitor report detailing fourth quarter 2022 VC investment, including a breakdown of biopharmaceutical fundraising in the US, but Pitchbook recently released its forecast for VC investment broadly across all industries in 2023, which mirrors trends taking place in recent years in the biopharma industry.

US venture capital investment across industries is expected to total $120bn-$130bn in 2023. That would be the lowest amount of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO

 
• By Mandy Jackson

Faeth Therapeutics raised $25m to complete a Phase II trial of its PIK3/mTOR-targeting drug combination in endometrial cancer and reported positive Phase II data at ESMO in ovarian cancer with half of the combo.

Cash Bonanza For European Oncology-Based Biotechs

 
• By Kevin Grogan

Adcytherix and Step Pharma join Tubulis in raising funds for their cancer drug projects.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

 
• By Anju Ghangurde

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

Kailera’s $600m Mega-Raise Signals Obesity Boom Is Not Slowing Down

 
• By Manas Mishra and Sushmita Panda

Kailera has chalked up its second massive fund raise in the space of a year as it seeks to begin a global trial of its dual GLP-1/GIP receptor agonist by the end of the year.

More from Business

China’s Next Wave Is First-In-Class Innovation

 
• By Jessica Merrill

Drug development in China was a discussion topic at the BioFuture conference as the country’s R&D investments begin to deliver first-in-class medicines.

Stock Watch: J&J’s $5bn Product Predictions Meet Investor Skepticism

 
• By Andy Smith

Despite announcing sales growth that is currently weathering the storm of one of its biggest losses of exclusivity and a spin-off of its orthopedic division, J&J’s stock price weakened after its earnings announcement. Investors probably wanted more visibility on MFN.

Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO

 
• By Mandy Jackson

Faeth Therapeutics raised $25m to complete a Phase II trial of its PIK3/mTOR-targeting drug combination in endometrial cancer and reported positive Phase II data at ESMO in ovarian cancer with half of the combo.